Developing a new scoring scheme for the Hemophilia Joint Health Score 2.1-Reference-Cited by-同舟云学术

Developing a new scoring scheme for the Hemophilia Joint Health Score 2.1

Published:2019-05-20 Issue:3 Volume:3 Page:405-411
ISSN:2475-0379
Container-title:Research and Practice in Thrombosis and Haemostasis
language:en
Short-container-title:Res Pract Thromb Haemost

Author:

Ribeiro Tiago¹,Abad Audrey²,Feldman Brian M.²³⁴

Affiliation:

1. Schulich School of Medicine & Dentistry Western University London Ontario Canada

2. Child Health Evaluative Sciences Program, Research Insititute The Hospital for Sick Children Toronto Ontario Canada

3. Department of Pediatrics Faculty of Medicine and the Institute of Health Policy Management & Evaluation Dalla Lana School of Public Health University of Toronto Toronto Ontario Canada

4. Division of Rheumatology The Hospital for Sick Children Toronto Ontario Canada

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/rth2.12212

Reference18 articles.

1. The past and future of haemophilia: diagnosis, treatments, and its complications

2. Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy

3. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

4. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy

5. Economic costs of hemophilia and the impact of prophylactic treatment on patient management;Chen SL;Am J Manag Care,2016

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Last 50 years of Hemophilia Care: A Golden Era;Indian Pediatrics;2024-05

2. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B;Cochrane Database of Systematic Reviews;2024-02-27

3. Noninterventional study assessing joint health in persons with hemophilia A after switching to turoctocog alfa pegol: design of pathfinderReal;Research and Practice in Thrombosis and Haemostasis;2024-02

4. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial;Blood Journal;2023-12-21

5. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study;The Lancet Haematology;2023-03